Zur Kurzanzeige

dc.contributor.authorHernández García, Ángela Patricia 
dc.contributor.authorRosales Fernández, Celia
dc.contributor.authorMiranda Vera, Carolina
dc.contributor.authorVeselinova Marinova, Anzhela
dc.contributor.authorGarcía Jambrina, Pablo 
dc.contributor.authorGarcía García, Pilar 
dc.contributor.authorDíez Martín, David 
dc.contributor.authorCastro González, María Ángeles 
dc.contributor.authorFuentes García, Manuel 
dc.date.accessioned2025-09-01T07:10:20Z
dc.date.available2025-09-01T07:10:20Z
dc.date.issued2024
dc.identifier.citationHernández, Á., Rosales‐Fernández, C., Miranda‐Vera, C., Veselinova, A., Jambrina, P. G., García‐García, P., García, P. A., Díez, D., Castro, M. Á., y Fuentes, M. (2025). Insights into podophyllotoxin lactone features: New cyclolignans as potential dual tubulin‐topoisomerase II inhibitors. Archiv Der Pharmazie, 358(1), e2400600. https://doi.org/10.1002/ardp.202400600es_ES
dc.identifier.issn0365-6233
dc.identifier.urihttp://hdl.handle.net/10366/166867
dc.descriptionFinanciación de acceso abierto proporcionada por los Fondos Europeos FEDER y la Junta de Castilla y León en el marco de la Estrategia de Investigación e Innovación para la Especialización Inteligente (RIS3) de Castilla y León 2021-2027es_ES
dc.description.abstract[EN] Chemomodulation of natural cyclolignans as podophyllotoxin has been a successful approach to obtain semisynthetic bioactive derivates. One example of this approach is the FDA‐approved drug etoposide for solid and hematological tumors. It differs from the antimitotic activity of the natural product in its mechanism of action, this drug being a topoisomerase II inhibitor instead of a tubulin antimitotic. Within the molecular requirements for the activity of these compounds, the trans‐γ‐lactone moiety presented in the parent compound has always been a feature to be explored to chemomodulate its bioactivity. In this study, we have obtained different compounds that comply with the molecular characteristics for antitubulin and antitopoisomerase II activity combined in a single molecule. Furthermore, we explored the influence of the trans‐lactone moiety on the final activity, finding that the cis‐lactone was also interesting in terms of bioactivity. The best values of cytotoxicity and cell cycle inhibition were obtained for a compound lacking the lactone ring, thus mimicking the podophyllic aldehyde functionalization, a selective antimitotic podophyllotoxin derivate. The analogs with cis‐lactone also presented interesting cytotoxic activity. The present study illustrates the potential of the chemomodulation of natural products such as natural cyclolignan podophyllotoxin derivates for the discovery of new antitumor agents.es_ES
dc.description.sponsorshipJunta de Castilla y León. Grant Number: SA076P20 Instituto de Salud Carlos III. Grant Numbers: PI21/01545, CB16/12/00400 CSIC's Global Health Platform. Grant Numbers: PTI + Salud Global, SGL2103027 Spanish Ministry of Science and Innovation. Grant Number: MCIN/AEI/10.13039/MCIN/AEI/10.13039/501100011033 Junta de Castilla y León and European Social Fond. Grant Number: EDU/1508/2020 European Social Fund. Grant Number: Orden EDU/842/2022 University of Salamanca. Grant Numbers: 18.K199, K240-463C01es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCytotoxicityes_ES
dc.subjectDual-activityes_ES
dc.subjectMolecular dynamicses_ES
dc.subjectNatural productses_ES
dc.subjectPodophyllic aldehydees_ES
dc.subject.meshPodophyllotoxin *
dc.subject.meshTubulin Modulators *
dc.titleInsights into podophyllotoxin lactone features: New cyclolignans as potential dual tubulin‐topoisomerase II inhibitorses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1002/ardp.202400600es_ES
dc.subject.unesco3209 Farmacologíaes_ES
dc.subject.unesco2302.07 Química Clínicaes_ES
dc.identifier.doi10.1002/ardp.202400600
dc.relation.projectIDSA076P20es_ES
dc.relation.projectIDPI21/01545es_ES
dc.relation.projectIDCB16/12/00400es_ES
dc.relation.projectIDSGL2103027es_ES
dc.relation.projectIDMCIN/AEI/10.13039/MCIN/AEI/10.13039/501100011033es_ES
dc.relation.projectIDEDU/1508/2020es_ES
dc.relation.projectIDEDU/842/2022es_ES
dc.relation.projectID18.K199es_ES
dc.relation.projectIDK240-463C01es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.essn1521-4184
dc.journal.titleArchiv der Pharmaziees_ES
dc.volume.number358es_ES
dc.issue.number1es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decspodofilotoxina *
dc.subject.decsmoduladores de la tubulina *


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Solange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: Attribution-NonCommercial-NoDerivatives 4.0 Internacional